Role of strontium ranelate in the therapy of osteoporosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F17%3A73580907" target="_blank" >RIV/61989592:15110/17:73580907 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00098892:_____/17:N0000085

Výsledek na webu

<a href="http://dx.doi.org/10.23937/2469-5726/1510050" target="_blank" >http://dx.doi.org/10.23937/2469-5726/1510050</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.23937/2469-5726/1510050" target="_blank" >10.23937/2469-5726/1510050</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Role of strontium ranelate in the therapy of osteoporosis

Popis výsledku v původním jazyce

Strontium ranelate is a medicine used to treat postmenopausal osteoporosis in women and osteoporosis in men. Preclinical data suggest its dual effect consisting of the control of bone resorption and promotion of bone formation. Admininstration of strontium ranelate leads to significant increase in the bone mass. Changes in bone density can be used to evaluate the adherence of patients as well as, in case of strontium ranelate, to etimate the fracture risk reduction. Clinical studies demonstrated its effect on reducing the risk of both vertebral and non-vertebral fractures, including fractures of the proximal femur. Currently, it is a second-line treatment of osteoporosis administered in case of intolerance, failure or contraindication of other therapy. Recently its cardiovascular safety was discussed. Contraindications of strontium ranelate in patients with ischemic heart disease, peripheral arterial desease, cerebrovascular disease or uncontrolled hypertension were added in 2013 to the wording of the Summary of Product Characteristics (SPC). Cohort and observational studies, however, did not clearly confirm the cardiovascular risk associated with administration of strontium ranelate. It is still a medicine indicated for treatment of osteoporosis with a favourable risk and benefit ratio.

Název v anglickém jazyce

Role of strontium ranelate in the therapy of osteoporosis

Popis výsledku anglicky

Strontium ranelate is a medicine used to treat postmenopausal osteoporosis in women and osteoporosis in men. Preclinical data suggest its dual effect consisting of the control of bone resorption and promotion of bone formation. Admininstration of strontium ranelate leads to significant increase in the bone mass. Changes in bone density can be used to evaluate the adherence of patients as well as, in case of strontium ranelate, to etimate the fracture risk reduction. Clinical studies demonstrated its effect on reducing the risk of both vertebral and non-vertebral fractures, including fractures of the proximal femur. Currently, it is a second-line treatment of osteoporosis administered in case of intolerance, failure or contraindication of other therapy. Recently its cardiovascular safety was discussed. Contraindications of strontium ranelate in patients with ischemic heart disease, peripheral arterial desease, cerebrovascular disease or uncontrolled hypertension were added in 2013 to the wording of the Summary of Product Characteristics (SPC). Cohort and observational studies, however, did not clearly confirm the cardiovascular risk associated with administration of strontium ranelate. It is still a medicine indicated for treatment of osteoporosis with a favourable risk and benefit ratio.

Druh

J_ost - Ostatní články v recenzovaných periodicích

CEP obor

—

OECD FORD obor

30218 - General and internal medicine

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Rheumatic Diseases and Treatment

ISSN

2469-5726

e-ISSN

—

Svazek periodika

3

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

6

Strana od-do

1-6

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—